ASND - Ascendis Pharma A/S
| Previous Close | 58.24 |
| Open | 57.34 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 100 |
| Day's Range | 57.04 - 58.36 |
| 52 Week Range | 35.31 - 76.99 |
| Volume | 90,778 |
| Avg. Volume | 121,973 |
| Market Cap | 2.395B |
| Beta (3Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.11 |
| Earnings Date | Nov 28, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.28 |
- GlobeNewswire•6 days ago
Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, November 28, 2018 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2018 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- GlobeNewswire•12 days ago
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced the formation of VISEN Pharmaceuticals (Visen), a joint venture with an investor syndicate led by Vivo Capital, to develop, manufacture and commercialize the company’s endocrinology rare disease therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
- GlobeNewswire•19 days ago
Ascendis Pharma A/S Announces Upcoming Investor Presentations
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the company will participate in two upcoming investor conferences. A live audio webcast of both events will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- GlobeNewswire•26 days ago
Market Trends Toward New Normal in Ascendis Pharma A/S, Diodes, Laureate Education, Randgold Resources, Fastenal, and LTC Properties — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Aurora Cannabis and Ascendis Pharma
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Major U.S. markets finished flat on Friday. For the third quarter, the S&P 500 Index jumped over 7 percent, its best quarter since 2013, while the Dow Jones ...
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Ascendis Pharma A/S, Fluor, InterDigital, Ruth's Hospitality Group, Aramark, and ManTech International — New Research Emphasizes Economic Growth
NEW YORK, Sept. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ASND earnings conference call or presentation 29-Aug-18 8:30pm GMT
Q2 2018 Ascendis Pharma A/S Earnings Call
Market Realist•2 months agoTransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on becoming a leading player in the endocrinology rare disease space by leveraging its TransCon technology to develop multiple prodrug therapies. The 12-month consensus analyst recommendation for Ascendis Pharma A/S on September 23 is a “strong buy.” The 12-month consensus target price for the company is $79, which is 18.80% higher than its last closing price on September 21. Ascendis Pharma A/S closed at $66.50 on September 21, 139.73% higher than its 52-week low of $27.74 and 13.63% lower than its 52-week high of $76.99.
- GlobeNewswire•2 months ago
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced its support of “Children’s Growth Awareness Week” taking place September 16-22, 2018, as a part of the company’s commitment to patients and to improving the lives of people with growth disorders. This initiative will be celebrated worldwide as “International Children's Growth Awareness Day” on September 20, 2018. 489, a resolution recognizing and supporting the goals and ideals of a “Growth Awareness Week,” to increase awareness in the community about the importance of what a child’s growth pattern can say about overall health.
- GlobeNewswire•2 months ago
Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences
COPENHAGEN, Denmark, Sept. 06, 2018-- Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced upcoming ...
- GlobeNewswire•3 months ago
Ascendis Pharma A/S Announces Upcoming Investor Presentations
COPENHAGEN, Denmark, Aug. 31, 2018-- Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the ...
Motley Fool•3 months agoAscendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript
ASND earnings call for the period ending June 30, 2018.
- GlobeNewswire•3 months ago
Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results
-Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon™ technology in a new therapeutic area-. -Conference Call Today at 4:30 p.m. Eastern Time-. COPENHAGEN, ...
- ACCESSWIRE•3 months ago
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 29, 2018 at 4:30 ...
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of ASND earnings conference call or presentation 30-May-18 8:30pm GMT
Q1 2018 Ascendis Pharma A/S Earnings Call
- ACCESSWIRE•6 months ago
Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Ascendis Pharma A/S (NASDAQ: ASND), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ASND as the Company's latest news hit the wire. On May 08, 2018, the Denmark-based biopharmaceutical Company announced that it has dosed the first subjects in a first-in-human Phase-1 trial of TransCon CNP, a long-acting prodrug of a C-type natriuretic peptide (CNP) in development as a therapeutic option for achondroplasia and potentially for other fibroblast growth factor receptor (FGFR)-related skeletal disorders. Active-Investors.com is currently working on the research report for Audentes Therapeutics, Inc. (NASDAQ: BOLD), which also belongs to the Healthcare sector as the Company Ascendis Pharma.